官宣！5家中国药企获得免费仿制生产辉瑞新冠口服药许可

澎湃新闻2022-03-18

辉瑞口服药的市场传言得到证实。3月17日，药品专利池（MPP）官网发布消息称，已与 35 家公司签署协议，这些企业被允许仿制生产辉瑞新冠口服药Paxlovid成分之一奈玛特韦（nirmatrelvir）。从官网公布的地图来看，协议涉及到的国家分布在全球12个国家，其中6家公司将专注于生产原料药，9家公司将生产药品，其余20家将两者兼而有之。中国有5家药企名列其中，包括华海药业、普洛药业、复星医药...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

请叫我骨神
2022-03-18
请叫我骨神
Great

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2220074660?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com/f2bb9162f10407908b68d91c8d440880","is_english":false,"pubTime":"2022-03-18 07:32","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2220074660","market":"sh","top_or_hot":-1,"title":"官宣！5家中国药企获得免费仿制生产辉瑞新冠口服药许可","media":"澎湃新闻","content":"<div>\n<p>辉瑞口服药的市场传言得到证实。3月17日，药品专利池 （MPP）官网发布消息称，已与 35 家公司签署协议，这些企业被允许仿制生产辉瑞新冠口服药Paxlovid成分之一奈玛特韦（nirmatrelvir）。从官网公布的地图来看，协议涉及到的国家分布在全球12个国家，其中6家公司将专注于生产原料药，9家公司将生产药品，其余20家将两者兼而有之。中国有5家药企名列其中，包括华海药业、普洛药业、复星医药...</p>\n\n<a href=\"https://finance.sina.com.cn/jjxw/2022-03-17/doc-imcwiwss6664359.shtml?finpagefr=p_115\">Source Link</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>官宣！5家中国药企获得免费仿制生产辉瑞新冠口服药许可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n官宣！5家中国药企获得免费仿制生产辉瑞新冠口服药许可\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 07:32 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/jjxw/2022-03-17/doc-imcwiwss6664359.shtml?finpagefr=p_115><strong>澎湃新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>辉瑞口服药的市场传言得到证实。3月17日，药品专利池 （MPP）官网发布消息称，已与 35 家公司签署协议，这些企业被允许仿制生产辉瑞新冠口服药Paxlovid成分之一奈玛特韦（nirmatrelvir）。从官网公布的地图来看，协议涉及到的国家分布在全球12个国家，其中6家公司将专注于生产原料药，9家公司将生产药品，其余20家将两者兼而有之。中国有5家药企名列其中，包括华海药业、普洛药业、复星医药...</p>\n\n<a href=\"https://finance.sina.com.cn/jjxw/2022-03-17/doc-imcwiwss6664359.shtml?finpagefr=p_115\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://finance.sina.com.cn/jjxw/2022-03-17/doc-imcwiwss6664359.shtml?finpagefr=p_115","article_id":"2220074660","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/f2bb9162f10407908b68d91c8d440880"],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2022-03-17/doc-imcwiwss6664359.shtml?finpagefr=p_115","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2220074660","pubTimestamp":1647559952,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"　　辉瑞口服药的市场传言得到证实。　　3月17日，药品专利池 官网发布消息称，已与 35 家公司签署协议，这些企业被允许仿制生产辉瑞新冠口服药Paxlovid成分之一奈玛特韦。　　也就是说，复星医药和上海迪赛诺两家药企获得了辉瑞和默沙东两款口服药的防治生产权益。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BK4534":"瑞士信贷持仓","BK4581":"高盛持仓","PFE":"辉瑞","BK4550":"红杉资本持仓"},"translate_title":"Official announcement! Five Chinese pharmaceutical companies obtained free imitation production of Pfizer COVID-19 oral medicine license","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/33873d3f81c008b7a7de48dc12057f62","symbols_score_info":{"PFE":1},"content_text":"辉瑞口服药的市场传言得到证实。3月17日，药品专利池 （MPP）官网发布消息称，已与 35 家公司签署协议，这些企业被允许仿制生产辉瑞新冠口服药Paxlovid成分之一奈玛特韦（nirmatrelvir）。从官网公布的地图来看，协议涉及到的国家分布在全球12个国家，其中6家公司将专注于生产原料药，9家公司将生产药品，其余20家将两者兼而有之。中国有5家药企名列其中，包括华海药业、普洛药业、复星医药、九洲药业、上海迪赛诺，其中九洲药业仅生产原料药，其他可以同时生产原料药和制剂。值得注意的是，该协议将帮助扩大辉瑞新冠口服药在95个中低收入国家的可及性，这约占53%的世界人口，但并不包括中国。值得关注的是，乌克兰的一家公司也在35家企业名单中。MPP称，由于当前的冲突，无法签署，但仍然可以使用该许可证。官网资料显示，药品专利池组织是联合国支持的公共卫生组织，致力于为中低收入国家增加获得救命药品的机会，并促进药品开发。当地时间1月20日，药品专利池组织（MPP）通过官网宣布，与27家药企签订协议，允许其为全球105个中低收入国家或地区生产及供应默沙东的口服抗新冠病毒药物Molnupiravir，以促进该药在全球的可负担性和可及性。复星医药、博瑞医药（维权）、石家庄龙泽制药、上海迪赛诺、朗华制药等5家中国药企名列其中，其中前四个获许可同时生产原料药和成品药，朗华制药获许生产原料药。也就是说，复星医药和上海迪赛诺两家药企获得了辉瑞和默沙东两款口服药的防治生产权益。辉瑞的Paxlovid是由PF-07321332和利托那韦合用的一种治疗方法，此前已经在国内获得附条件上市批准。默沙东的Molnupiravir是一款在研口服形式的核苷类药物，尚未在国内获批。3月17日早些时候，市场就流传上述消息，上述上市公司一度涨停。此前市场传言，普洛药业仅可生产原料药。从最新公布的地图来看，普洛药业可以生产原料药，也可生产制剂。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9035888517,"gmtCreate":1647563819338,"gmtModify":1676534244656,"author":{"id":"3583374014261173","authorId":"3583374014261173","name":"请叫我骨神","avatar":"https://static.tigerbbs.com/503b4d06061954e26664c0601cf2936e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583374014261173","authorIdStr":"3583374014261173"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035888517","repostId":2220074660,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":54,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2220074660"}